Common Contracts
9 similar null contracts by Interpace Diagnostics Group, Inc., Adamis Pharmaceuticals Corp, Cesca Therapeutics Inc., others
EX-1.1 2 d426939dex11.htm EX-1.1 Execution Version August 25, 2016 Mr. John Glass Interim Chief Financial Officer Provectus Biopharmaceuticals, Inc.New York • May 5th, 2020
Jack E. Stover President and Chief Executive Officer Morris Corporate Center 1, Building A 300 Interpace Parkway Parsippany, NJ 07054 Dear Mr. Stover:Interpace Diagnostics Group, Inc. • January 20th, 2017 • Surgical & medical instruments & apparatus • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of 855,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), and warrants (the “Warrants”) to purchase an aggregate of 855,000 shares of Common Stock (the “Warrant Shares”) pursuant to an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder. The Shares, Warrants and Warrant Shares are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Secu
Jack E. Stover President and Chief Executive Officer Morris Corporate Center 1, Building A 300 Interpace Parkway Parsippany, NJ 07054 Dear Mr. Stover:Interpace Diagnostics Group, Inc. • January 5th, 2017 • Surgical & medical instruments & apparatus • New York
This letter (the “Agreement”) constitutes the amended and restated agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), effective as of January 3, 2017, that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of up to 630,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”). This Agreement hereby amends and restates that certain letter agreement, dated January 3, 2017, by and between the Placement Agent and the Company. The Shares are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim has or would have the power or authority to
Jack E. Stover President and Chief Executive Officer Morris Corporate Center 1, Building A 300 Interpace Parkway Parsippany, NJ 07054 Dear Mr. Stover:Interpace Diagnostics Group, Inc. • January 3rd, 2017 • Surgical & medical instruments & apparatus • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of up to 375,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), and prepaid warrants (the “Warrants”) to purchase an aggregate of 255,000 shares of Common Stock (the “Warrant Shares”). The Shares, Warrants and Warrant Shares are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim has or would have the power or authority to bind the Company or any Purchaser or an obligation f
Jack E. Stover President and Chief Executive Officer Morris Corporate Center 1, Building A 300 Interpace Parkway Parsippany, NJ 07054 Dear Mr. Stover:Interpace Diagnostics Group, Inc. • December 19th, 2016 • Surgical & medical instruments & apparatus • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of 2,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), and prepaid warrants (the “Warrants”) to purchase an aggregate of 1,600,000 shares of Common Stock (the “Warrant Shares”). The Shares, Warrants and Warrant Shares are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim has or would have the power or authority to bind the Company or any Purchaser or an obligation for
August 25, 2016Provectus Biopharmaceuticals, Inc. • August 25th, 2016 • Pharmaceutical preparations • New York
Robin C. StraceyCesca Therapeutics Inc. • August 4th, 2016 • Laboratory apparatus & furniture • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Cesca Therapeutics Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of 600,000 shares of (the “Securities”) of the Company’s common stock, par value $0.001 per share (“Common Stock”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement, including but not limited to the Purchase Agreem
ADAMIS PHARMACEUTICALS CORPORATION 8-KAdamis Pharmaceuticals Corp • July 29th, 2016 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of 3,573,255 shares of (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and warrants to purchase up to 3,573,255 of the shares of Common Stock (each a “Warrant” and collectively, the “Warrants”). The Shares, the Warrants and the shares of Common Stock underlying the Warrants (the “Warrant Shares”) are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or autho
Christopher J. Reed Chief Executive Officer 13000 South Spring Street Los Angeles, California 90061Reed's, Inc. • June 3rd, 2016 • Bottled & canned soft drinks & carbonated waters • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Reeds, Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of an aggregate of 692,412 shares of (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) and warrants to purchase up to 346,206 of the shares of Common Stock (each a “Warrant” and collectively, the “Warrants”). The Shares, the Warrants and the shares of Common Stock underlying the Warrants (the “Warrant Shares”) are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind th
